TABLE 2.
Reinfection studya
| Expt | Site | Experimental groupb | No. of CFUc
|
||
|---|---|---|---|---|---|
| Day 14 | Day 28 | Day 42 | |||
| 1 | Lung | Naive | 5.21 ± 0.17 | 5.36 ± 0.15 | 4.90 ± 0.07 |
| DNA | 4.61 ± 0.19 (−0.60) | 4.39 ± 0.18 (−0.97) | 4.50 ± 0.13 (−0.40) | ||
| Chronic | 4.04 ± 0.11 (−1.17) | 4.33 ± 0.21 (−1.03) | 3.99 ± 0.22 (−0.91) | ||
| Drug treated | 4.61 ± 0.13 (−0.60) | 4.47 ± 0.15 (−0.89) | 4.22 ± 0.18 (−0.68) | ||
| Drug treated + DNA | 4.21 ± 0.05 (−1.00)d | 4.14 ± 0.12 (−1.22)d | 4.10 ± 0.14 (−0.80) | ||
| Drug treated + vector | 4.52 ± 0.11 (−0.69) | 4.50 ± 0.29 (−0.85) | 4.36 ± 0.20 (−0.54) | ||
| Spleen | Naive | 4.60 ± 0.36 | 4.25 ± 0.10 | ||
| DNA | 3.81 ± 0.52 (−0.79) | 3.61 ± 0.35 (−0.64) | |||
| Chronic | <2e | <2 (−2.25) | |||
| Drug treated | <2 | 2.96 ± 0.15 (−1.29) | |||
| Drug treated + DNA | <2 | 2.46 ± 0.45 (−1.77) | |||
| Drug treated + vector | <2 | 2.32 ± 0.33 (−1.93) | |||
| 2 | Lung | Naive | 4.50 ± 0.34 | 4.74 ± 0.17 | 4.56 ± 0.11 |
| Chronic | 3.28 ± 0.06 (−1.22) | 3.34 ± 0.12 (−1.40) | 3.52 ± 0.30 (−1.04) | ||
| Drug treated | 3.95 ± 0.28 (−0.55) | 4.01 ± 0.05 (−0.73) | 4.18 ± 0.10 (−0.36) | ||
| Drug treated + DNA | 3.57 ± 0.07 (−0.93)d | 3.65 ± 0.16 (−1.09)d | 3.91 ± 0.43 (−0.65) | ||
| Spleen | Naive | 3.99 ± 0.17 | 4.19 ± 0.24 | ||
| Chronic | <2 | <2 (−2.19) | |||
| Drug treated | <2 | 2.12 ± 0.23 (−2.07) | |||
| Drug treated + DNA | <2 | 2.08 ± 0.15 (−2.11) | |||
The naïve and DNA groups of mice were aerogenically challenged with an Acr M. tuberculosis Erdman strain as a primary infection. The other groups of mice were aerogenically challenged with the same acriflavin resistant strain following the initial intravenous M. tuberculosis H37Rv infection and the subsequent DNA vaccinations. The CFU numbers represent only the growth of the acriflavin-resistant challenge strain on Middlebrook 7H11 agar containing 10 μg of acriflavin/ml.
DNA, naïve mice immunized with the DNA vaccine combination; chronic, H37Rv primary infection only; drug treated, H37Rv primary infection followed by INH and RIF chemotherapy; drug treated + DNA, primary infection followed by chemotherapy and DNA vaccination; drug treated + vector, primary infection followed by chemotherapy and injection of the vector control.
Mean CFU log10 ± standard deviation; the numbers in parentheses represent the log10 reduction in CFU in experimental mice relative to that in naïve mice.
Drug-treated + DNA group is significantly less than drug-treated group (P < 0.05).
Limit of detection of the assay is 100 CFU/organ (2 log10).